BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Inozyme Pharma, Inc. (Nasdaq: INZY) announce that BioMarin has entered into a definitive agreement to acquire Inozyme for $4.00 per share in an all-cash transaction for a total consideration of approximately $270 million. The acquisition will strengthen BioMarin’s enzyme therapies portfolio, adding a late-stage enzyme replacement therapy, INZ-701, which is currently being assessed for the treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) Deficiency, a rare, serious and progressive genetic condition that affects blood vessels, soft tissues and bones.
Read the full article: BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma //
Source: https://www.prnewswire.com/news-releases/biomarin-strengthens-enzyme-therapy-business-with-acquisition-of-inozyme-pharma-302457584.html